Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
Status:
Completed
Trial end date:
2017-02-27
Target enrollment:
Participant gender:
Summary
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group
study using avatrombopag to treat adults with thrombocytopenia associated with liver disease.
The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with
liver disease prior to an elective procedure to reduce the need for platelet transfusions or
any rescue procedure for bleeding due to procedural and post-procedural bleeding
complications. Participants will be enrolled into 2 cohorts according to mean baseline
platelet count and, within each baseline platelet count cohort will be further stratified by
risk of bleeding associated with the elective procedure (low, moderate, or high) and
hepatocellular carcinoma (HCC) status (Yes or No).